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3%. The cost-effectiveness ratio was expressed as cost of
life year gained with RSV prophylaxis. Sensitivity analy-
ses were performed for the key probabilities. RESULTS:
Palivizumab prophylaxis was estimated to cost €8903 per
life gained as compared to €6594 for no preventive treat-
ment. The incremental cost-effectiveness ratio of one life
year gained amounted to €13,246 (PPP: €1 = 1.9 PLN).
The sensitivity analysis indicated that the results were sen-
sitive to the probability of hospitalization for RSV for 
no prophylaxis. CONCLUSIONS: Palivizumab, as com-
pared to other widely accepted medical procedures,
appeared to be cost-effective prophylaxis for the preven-
tion of serious lower respiratory-tract infection caused by
RSV in infants born at less than 32 weeks gestation in
Poland.
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OBJECTIVES: The objective is to discuss and evaluate
potential changes in patient, physician, and organisa-
tional behavior related to the introduction of a new health
care technology (treatment of inﬂuenza with the anti-viral
neuraminidase inhibitors). The changes evaluated are: 1)
increased health care seeking by patients, due to the avail-
ability of antivirals for inﬂuenza; 2) Crowding out of
inappropriate anti-biotic prescribing for inﬂuenza by
antivirals; and 3) System change to allow telephone nurse
prescribing rather than GP consultation. METHODS:
Some unique characteristics of neuramindase inhibitors
has important implications for their cost-effectiveness 
in any given health care systems. A health economic 
decision model is employed in order to evaluate some of
these potential changes when introducing treatment of
inﬂuenza with neuraminidase inhibitors. The impact on
cost-effectiveness and cost-utility of three different behav-
ioural changes are investigated with the model as well as
the base line cost-effectiveness and cost-utility of treating
healthy adults in UK. RESULTS: The results of the eco-
nomic modeling show that treatment of inﬂuenza in
healthy adults with the anti-viral oseltamivir has incre-
mental cost-utility ratios between £4,775/QALY (base-
line) and £15,772/QALY (increased health care seeking
by patients). CONCLUSION: In order to make a deci-
sion regarding introduction of inﬂuenza treatment with
the new technology a number of issues ought to be
addressed. These may be best dealt with in a full HTA
where all aspects of introducing a new technology are
investigated. By only evaluating certain aspects of the
introduction of the technology, decision makers are likely
to make decisions based on incomplete information. This
may result in sub-optimal patient treatment and resource
use in society.
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OBJETIVE: The hepatitis C treatment with conven-
tional interferon monotherapy has been under discussion
because of its low response rate (10–20%). However,
combination therapies involving ribavirin and the new
two pegylated interferons have raised the response rates
beyond 50%. This study analyses the cost-effectiveness
ratios for two different peginterferons (peginterferon alfa-
2a and peginterferon alfa-2b) plus ribavirin compared
with interferon-alfa 2b plus ribavirin. METHOD: A
Markov model was developed to represent the natural
history of hepatitis C and to estimate the incremental
cost-effectiveness ratios for the two different peginterfer-
ons plus ribavirin compared with interferon-alfa 2b plus
ribavirin. The results of two indipendent clinical trials
comparing these treatment alternatives in naive patients
with HCV infection and no co-morbidity have been
obtained from several publications. The model was
applied separately to both trials. To evaluate the natural
history of decompensated cirrhosis, 200 patients with
decompensated liver disease from hepatitis C etiology
were studied depending on the ﬁrst decompensation event
in two different hospitals in Spain. RESULTS: The results
indicate costs of €20,751/life-year gained using efﬁcacy
data from the peginterferon alfa-2b trial and €10,350/life-
year gained employing the peginterferon alfa-2a trial
data. When a test is used at 12 weeks to facilitate an early
detection of non-responders, the ﬁgures lower to €14,037
and €6,605/life-year gained, respectively. CONCLU-
SION: The main conclusion is that the combined treat-
ment of peginterferon plus ribavirin is cost-effective
showing peginterferon alfa-2a a better cost-effectiveness
ratio than peginterferon alfa-2b. Efﬁciency decreases with
advancing age and can be increased when strategies of
early selection are employed to identify those patients
who, without sustained viral response, would not beneﬁt
from the treatment.
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OBJECTIVE: To estimate the patterns of medical care
and associated direct medical costs of managing chronic
hepatitis B virus (HBV) in France. METHOD: Five stages
were identiﬁed to describe the natural history of the
disease: Chronic hepatitis B without complications, com-
pensated cirrhosis, decompensated cirrhosis, hepatic
transplantation (ﬁrst and second year), and hepatocellu-
lar carcinoma. Standard care and corresponding items of
medical resources for these different states of health were
deﬁned on the basis of a literature review and the con-
clusions of an experts panel. Resources included ofﬁces
visits, procedures, laboratory tests, drugs (including
antiviral drugs), and hospitalizations. For each state, the
annual mean unit direct medical costs were estimated
using the weighted proportion of patients using the
resource. Unit costs (2001 value) were nationally avail-
able from the perspective of the French national insur-
ance. RESULTS: Approximately 24% of HBV patients
are managed with antivirals but these medications
accounted for approximately 45% and laboratory tests
for 30% of treatment costs in the chronic HBV state
(€1093). The mean annual treatment costs for the more
advanced disease states were: compensated cirrhosis
€1134, decompensated cirrhosis €8842 (due primarily to
hospital admissions), hepatic transplantation €84,568
(ﬁrst year) and €9147 (second year), and hepatocellular
carcinoma €9352. CONCLUSIONS: Treatment patterns
for HBV vary across centers in France. The average treat-
ment costs indicate a substantial ﬁnancial burden of HBV
that increases with advanced stages of the disease. Pre-
venting HBV or its advance could result in lowered long-
term treatment expenditures.
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OBJECTIVES: To estimate the prevalence and the quality
of life of subjects suffering from Herpes labialis (HL) in
the French population of adults above 17 years old.
METHODS: A population-based survey was conducted
among 10,000 adults through personal face to face inter-
views by using the quota sampling method (applied on
age, sex, economic working class and woman working
status). The screening was made by asking the subjects if
they have suffered from HL or if they have experienced
a fever blister, within the past 12 months. The quality of
life was assessed with the SF-36 questionnaire among 
the HL subjects identiﬁed and a control group of subjects
not suffering from HL (361 subjects). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. The annual prevalence of HL was estimated: 15.1%,
IC95%[14.1%; 16.1%]. The sex ratio women/men was
2/1 and the mean age was 41 years at the time of the study
versus 47.4 years in the control group (p < 0.01). Among
the HL population 14.2% experienced at least 6 recur-
rences in the past 12 months with a sex ratio women/
men at 3/1. The quality of life was worse in the HL 
population with at least 6 recurrences in the past 12
months than in the control group for both physical 
and mental health. After adjustment on age and sex, SF
36-scores were respectively 47.6 vs. 50.8 for physical
health (p < 0.05) and 45.3 vs. 47.9 for mental health (p
< 0.05). CONCLUSIONS: Herpes Labialis is a common
disease in France with an annual prevalence of 15% in
France. When occurring with at least 6 recurrences in 
the past 12 months, Herpes Labialis has a signiﬁcant
impact on quality of life, as measured by the SF-36 
questionnaire.
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OBJECTIVES: No measure has been available to assess
the impact of recurrent genital herpes (RGH) outbreaks.
Some herpes interventions attempt to abort an outbreak
or reduce its length and/or severity. An instrument was
required to determine the beneﬁt of such interventions
from the patients’ perspective, in the context of a clinical
trial. The objective was to develop a measure of the
impact of outbreaks using items representing functional
limitations of speciﬁc importance to RGH patients.
METHODS: Content was derived via interviews with
RGH patients (n = 40). Face & content validity of the
draft HOIQ were assessed by cognitive de-brieﬁng inter-
views with RGH patients (n = 19). Scaling/psychometric
properties were assessed via a web-survey, whereby par-
ticipants (n = 158) completed the HOIQ on two occa-
sions during an outbreak, with 24 to 72 hours between
administrations. RESULTS: Interviews revealed areas of
functioning affected during an outbreak to include; social,
work and other activities, relationships, personal hygiene,
choice of clothing, need to avoid becoming tired,
worry/anxiety and fear of discovery. De-brieﬁng inter-
views indicated that content was appropriate and the
measure easy to understand and complete. Rasch analy-
sis of survey data yielded a 12-item unidimensional
measure. Assessment of test-retest reliability was not pos-
sible due to rapid change in health status during an out-
break. However, item stability testing indicated that no
items exhibited time-related differential item functioning,
